Video Series: Current Topics in the Treatment of Advanced PCa
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.
Latest Prostate Cancer News
Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.
Research emphasizes the need for nationwide refinements in the prostate cancer screening process.
In a small study, some men whose cancer progressed while on enzalutamide had a profound PSA response to pembrolizumab.
Adjusted odds ratio of prostate cancer significantly higher for MRI score than PSA.
Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.
Swedish researchers say their findings are more useful for counseling men with a family history of prostate cancer.
Study results strengthen researchers' arguments for further clinical trials evaluating the potential protective effect of statins.
Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.
Preliminary findings suggest a field effect in prostate cancer.
Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.
Odds of using this strategy are 2.7-fold greater vs community facilities.
Genetic testing results could help guide therapy for advanced prostate cancer.
For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.
About 10% of patients with clinically localized prostate cancer have lymphovascular invasion on their prostatectomy specimen.
Use of active surveillance increasing, active treatment decreasing for low-risk disease.
Prostate Cancer Videos
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)